[68Ga]Ga-FAPI Surpasses [18F]FDG in Pancreatic Adenosquamous Carcinoma Restaging

Clinical Nuclear Medicine 2026

View at publisher
Authors: Ahmed Saad Abdlkadir, Hussam Haddad, Issa Mohamad, Akram Al‐Ibraheem
DOI: 10.1097/rlu.0000000000006284
Cited by: 0
References: 8

Abstract

Pancreatic adenosquamous carcinoma (PASC) represents a rare, aggressive exocrine neoplasm. We describe a 33-year-old woman with an aggressive disease trajectory and limited survival. Baseline [18F]FDG PET/CT enabled accurate staging and treatment planning of stage IV malignancy. Following FOLFIRINOX chemotherapy, complete metabolic resolution was achieved on follow-up [18F]FDG PET/CT. Nevertheless, disease relapse ensued within 5 months. During restaging, [18F]FDG PET/CT failed to reveal any hypermetabolic lesions, whereas [68Ga]Ga-FAPI PET/CT successfully identified both local and metastatic recurrences. Notably, this case highlights the superiority of [68Ga]Ga-FAPI PET/CT for detecting recurrent PASC compared with [18F]FDG PET/CT.

Fields of Study & Subjects

Peptidase Inhibition and Analysis Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances

Publication details

Journal / source
Clinical Nuclear Medicine
Volume
51
Issue
3
Pages
250–251
Publication date
3 February 2026
Language
EN